Age and disability accumulation in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: We tested the hypothesis that age is a prognostic factor with respect to long-term accumulation of disability in multiple sclerosis (MS).
Methods: Kaplan-Meier analysis and binary logistic regression models determined the effect of age at disease onset, age at onset of progression, and current age on attainment of severe disability levels (Disability Status Scale [DSS] 6–8–10) from the London, Ontario, database (n = 1,023).
Results: Older age at relapsing-remitting (RR) phase onset was associated with higher risk of reaching advanced DSS scores. This was independent of disease duration and early relapse frequency but secondary to increased risk of conversion to secondary progressive (SP) MS. Onset at age 40 (odds ratio [OR] = 4.22) and at age 50 (OR = 6.04) doubled and tripled risks of developing SP, compared to age 20 (OR = 2.05). Younger age at conversion to SPMS was associated with shorter times to high DSS scores from disease onset. The progressive course, unaffected by age at RR onset, was only modestly affected by age at SP onset. Among primary progressive and RR/SP patients, median ages at attainment of DSS scores were strikingly similar: DSS = 6, 49 vs 48 years; DSS = 8, 58 vs 58 years; and DSS = 10, 78 years for both (p = NS for all comparisons).
Conclusions: Development of SP is the dominant determinant of long-term prognosis, independent of disease duration and early relapse frequency. Age independently affects disability development primarily by changing probability and latency of SP onset, with little effect on the progressive course.
GLOSSARY
- CI=
- confidence interval;
- DMT=
- disease-modifying therapy;
- DSS=
- Disability Status Scale;
- MC=
- Middlesex County;
- MS=
- multiple sclerosis;
- OR=
- odds ratio;
- PP=
- primary progressive;
- PR=
- progressive relapsing;
- RR=
- relapsing-remitting;
- SO=
- patients seen from disease onset;
- SP=
- secondary progressive
Footnotes
-
Study funding: Supported by the Italian Multiple Sclerosis Foundation (FISM; ref. 2008/R/16), the Medical Research Council (Ref. G0800679), The MS Society of Canada, the UK MS Society, and the “Kompetenznetz Multiple Sklerose” (Competence Network for Multiple Sclerosis) funded by the Federal Ministry of Education and Research (BMBF) (FKZ 01Gl0904, 01Gl0920).
- Received March 3, 2011.
- Accepted May 23, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosisAntonio Scalfari, Chiara Romualdi, Richard S. Nicholas et al.Neurology, May 16, 2018 -
Article
Relapses and disability accumulation in progressive multiple sclerosisM. Mateo Paz Soldán, Martina Novotna, Nuhad Abou Zeid et al.Neurology, November 14, 2014 -
Articles
Clinical and laboratory features of primary progressive and secondary progressive MSKhurram Bashir, John N. Whitaker et al.Neurology, September 01, 1999 -
Articles
Cigarette smoking and progression in multiple sclerosisMarcus Koch, Annemarie van Harten, Maarten Uyttenboogaart et al.Neurology, October 08, 2007